이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NanoViricides 미래 성장

Future 기준 확인 0/6

NanoViricides은 연간 수입과 매출이 각각 7.8%와 72.9% 증가할 것으로 예상되고 EPS는 연간 16.1%만큼 증가할 것으로 예상됩니다.

주요 정보

7.8%

수익 성장률

16.1%

EPS 성장률

Biotechs 수익 성장	24.1%
매출 성장률	63.0%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	20 May 2024

최근 미래 성장 업데이트

Recent updates

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

Feb 18

수익 및 매출 성장 예측

NYSEAM:NNVC - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2027	7	-6	-4	-4	1
6/30/2026	3	-8	-5	-5	1
6/30/2025	N/A	-11	-9	-8	2
6/30/2024	N/A	-7	-6	-6	2
3/31/2024	N/A	-10	-6	-6	N/A
12/31/2023	N/A	-9	-6	-6	N/A
9/30/2023	N/A	-9	-6	-6	N/A
6/30/2023	N/A	-9	-6	-6	N/A
3/31/2023	N/A	-7	-6	-6	N/A
12/31/2022	N/A	-7	-6	-5	N/A
9/30/2022	N/A	-7	-7	-6	N/A
6/30/2022	N/A	-8	-6	-6	N/A
3/31/2022	N/A	-8	-7	-7	N/A
12/31/2021	N/A	-9	-7	-7	N/A
9/30/2021	N/A	-9	-7	-7	N/A
6/30/2021	N/A	-9	-8	-8	N/A
3/31/2021	N/A	-9	-8	-8	N/A
12/31/2020	N/A	-15	-9	-9	N/A
9/30/2020	N/A	-14	-8	-7	N/A
6/30/2020	N/A	-13	-7	-7	N/A
3/31/2020	N/A	-14	-7	-7	N/A
12/31/2019	N/A	-8	-6	-6	N/A
9/30/2019	N/A	-8	-7	-7	N/A
6/30/2019	N/A	-8	-7	-7	N/A
3/31/2019	N/A	-8	-9	-9	N/A
12/31/2018	N/A	-8	-8	-8	N/A
9/30/2018	N/A	-8	-7	-7	N/A
6/30/2018	N/A	-9	-8	-8	N/A
3/31/2018	N/A	-9	-6	-5	N/A
12/31/2017	N/A	-10	N/A	-6	N/A
9/30/2017	N/A	-9	N/A	-7	N/A
6/30/2017	N/A	-10	N/A	-8	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-11	N/A	-9	N/A
9/30/2016	N/A	-12	N/A	-7	N/A
6/30/2016	N/A	-11	N/A	-7	N/A
3/31/2016	N/A	-10	N/A	-7	N/A
12/31/2015	N/A	-5	N/A	-6	N/A
9/30/2015	N/A	-4	N/A	-6	N/A
6/30/2015	N/A	-2	N/A	-6	N/A
3/31/2015	N/A	-8	N/A	-6	N/A
12/31/2014	N/A	-7	N/A	-6	N/A
9/30/2014	N/A	-6	N/A	-7	N/A
6/30/2014	N/A	-14	N/A	-6	N/A
3/31/2014	N/A	-9	N/A	-7	N/A
12/31/2013	N/A	-14	N/A	-7	N/A

애널리스트 미래 성장 예측

수입 대 저축률: NNVC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: NNVC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: NNVC 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: NNVC 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: NNVC 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: NNVC 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

NanoViricides 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 38% to US$5.25

Recent updates

NanoViricides, Inc. Announces Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virusilling, Technology Platform Intending to Revolutionize Treatment of Viral Infections

Nanoviricides, Inc. Reports Nv-387 Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon

New major risk - Financial position

NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found

Insufficient new directors

NanoViricides, Inc., Annual General Meeting, Jan 13, 2024

NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2

Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development

Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2

New major risk - Revenue and earnings growth

Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides

Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well

Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

New major risk - Share price stability

Price target decreased by 38% to US$5.25

NanoViricides, Inc., Annual General Meeting, Feb 07, 2023

NanoViricides, Inc., Annual General Meeting, Dec 17, 2022

NanoViricides, Inc. announced delayed annual 10-K filing

NanoViricides, Inc. Reports Advantages Gained by Remdesivir Encapsulation

NanoViricides, Inc.(NYSEAM:NNVC) dropped from Russell Microcap Growth Index

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

New 90-day high: US$5.49

Consultant has left the company

New 90-day high: US$4.43

New 90-day low: US$3.08

Nanoviricides, Inc. Announces Board Changes

NanoViricides, Inc. announced delayed annual 10-K filing

New 90-day low: US$3.81

NanoViricides, Inc. Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

New 90-day low - US$5.57

NanoViricides, Inc. has completed a Follow-on Equity Offering in the amount of $10 million.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견